ASX-Dividend-Report-Banner

Cicada Innovations launches HealthTech Hub in Western Sydney's "hidden innovation ecosystem"

March 26, 2024 01:00 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
Image source: Kalkine Media

SYDNEY, March 26, 2024 /PRNewswire/ -- Australia's flagship deep tech incubator Cicada Innovations is officially opening the doors to the "Cicada HealthTech Hub" on 25 March 2024, officiated by the Hon. Anoulack Chanthivong, Minister for Innovation, Science and Technology.

(L-R) Hon. Anoulack Chanthivong, Minister for Innovation, Science and Technology, and Sally-Ann Williams, CEO of Cicada Innovations
(L-R) Hon. Anoulack Chanthivong, Minister for Innovation, Science and Technology, and Sally-Ann Williams, CEO of Cicada Innovations

The world-class incubation facility is supported by a grant from Investment NSW, and will be situated within one of Australia's largest health and biomedical precincts, the Westmead Health and Innovation District, located in Sydney's Western Suburbs.

Incubation is now open to pre-revenue stage startups, spinouts, research projects, and more established businesses looking for a landing pad in areas of medical technology and devices such as cell and gene therapy, cancer research, infectious diseases, immunology, and vaccines.

Benefits include affordable and flexible workspaces, dedicated facilities, critical connections, and curated support services, all aimed at facilitating the rapid commercialisation of life-changing research with real patient outcomes.

The first resident already on site is iiSheild, a healthtech startup whose groundbreaking "kidney pyjamas" (Ischemic Injury Protective Jacket) aim to double the available time for kidney transplants by minimising the heat of the kidney during procedures.

iiShield originated in Westmead then moved into Cicada Innovations' Eveleigh site as it completed the Cicada-run NSW Health Commercialisation Training Program, then moved back to Westmead to be closer to precinct, progress clinical trials, and raise its next round of capital.

Residents like iiShield will benefit from being located in a district that boasts four major hospitals, four world-leading medical research institutions, two university campuses and the largest research-intensive pathology service in NSW.

Western Sydney more broadly also offers a rapidly-growing diverse population of 2.5 million people and over 1000 clinical trials including some of Australia's biggest, while Australia's first commercial-scale viral vector manufacturing facility is currently being built in the precinct.

All of these factors and more make Western Sydney one of Australia's most critical "hidden innovation gems" according to Cicada Innovations CEO, Sally-Ann Williams.

Sally-Ann Williams, CEO of Cicada Innovations, said: "Western Sydney may not be the first location that springs to mind when we think 'innovation'. But when you look at the groundbreaking work coming from the precinct, it really could be considered one of Australia's most exciting hidden innovation gems.

"Companies like iiShield, originating in Westmead, offer a perfect case study of the journey Australia's most critical medtech companies take from research lab to commercialisation to the homes and industries where they will positively impact the largest number of people.

"We're excited to now be calling for many more iiShields to come and take advantage of these state-of-the art facilities and the many benefits the growing precinct has to offer."

Hon. Anoulack Chanthivong, Minister for Innovation, Science and Technology said: "The HealthTech Hub will play a vital role in driving biotech, medtech and pharmaceutical industry development in NSW by bringing our world class health researchers and entrepreneurs together. It will support early-stage startups to build capability, fast-tracking commercialisation and helping to grow our state's future skills pipeline.

"The Hub is a great example of how the NSW Government is working with organisations like Cicada to build a collaborative, inclusive and more supportive innovation ecosystem."

Cicada Innovations will deliver the new health-focused program alongside Australasia's leading life science VC firm, Brandon Capital.

Brandon Capital will also play a role in supporting commercial outcomes through participation in Cicada's commercialisation programs, mentoring, and support for innovators in the precinct.

Cicada Innovations is urging all aspiring medtech founders and innovators to explore residency opportunities by leaving their details as an expression of interest here.

Cicada Innovations is the home of deep tech in Australia. Founded in Sydney, Cicada Innovations has a 23-year track record of developing deep tech ventures that tackle some of the world's most pressing problems.           

Cicada's national incubators, commercialisation training, and community brings together the entrepreneurs, scientists, business leaders, and policymakers to solve complex challenges with deep tech like the future of human health, food security and the climate crisis.         

Since its inception more than two decades ago, Cicada has seen an unprecedented $1.3 billion in exits from six deep tech ventures, and has helped over 300 companies raise more than $1.8 billion in funding. It has twice been named the 'Top Incubator in the World' by the International Business Innovation Association and has delivered commercialisation training to thousands working in the science and technology sectors.

Third Hemisphere is Cicada Innovations' PR & Marketing Agency in Sydney

 

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.